Adaptive Biotechnologies Cash Flow Statement
NASDAQ: ADPTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Adaptive Biotechnologies free cash flow
In fiscal 2025, Adaptive Biotechnologies generated -$46.0 million of operating cash flow and spent $3.0 million on capital expenditures. That left free cash flow of -$48.9 million, a free-cash-flow margin of -17.7% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Adaptive Biotechnologies cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -59.46M | -159.59M | -225.30M | -200.37M | -207.30M | -146.23M | -68.61M | -46.45M | -42.83M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 16.00M | 17.44M | 19.60M | 20.92M | 12.25M | 6.77M | 6.09M | 4.30M | 4.10M |
| Stock-Based Compensation | 51.48M | 53.61M | 62.91M | 55.48M | 43.25M | 24.76M | 13.12M | 11.15M | 7.01M |
| Change in Working Capital | -47.46M | -8.10M | -37.43M | -67.67M | -65.06M | -39.64M | 255.45M | -1.05M | -4.44M |
| Operating Cash Flow | -45.99M | -95.21M | -156.32M | -183.94M | -192.73M | -149.68M | 205.40M | -32.26M | -34.86M |
| Capital Expenditures | -2.96M | -3.66M | -10.70M | -16.35M | -61.75M | -18.80M | -11.20M | -6.30M | -2.42M |
| Investing Cash Flow | 37.95M | 77.79M | 129.65M | 2.90M | 181.21M | -117.04M | -481.70M | 736.00K | 36.43M |
| Financing Cash Flow | 30.40M | 241.00K | 2.25M | 132.26M | 27.15M | 293.59M | 319.92M | 1.25M | 50.03M |
| Net Change in Cash | 22.37M | -17.18M | -24.43M | -48.77M | 15.63M | 26.86M | 43.62M | -30.27M | 51.61M |
| Free Cash Flow | -48.95M | -98.88M | -167.02M | -200.29M | -254.47M | -168.49M | 194.20M | -38.56M | -37.28M |
This table shows 9 annual periods of Adaptive Biotechnologies's cash flow statement, from FY 2025 back to FY 2017, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ADPT's reporting calendar. What is a cash flow statement?